Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
04/20/2017 04/21/2017 04/24/2017 04/25/2017 04/26/2017 Date
252.4(c) 249.7(c) 250(c) 253.7(c) 255.1 Last
2 350 802 3 082 091 3 594 338 4 142 286 869 019 Volume
-0.24% -1.07% +0.12% +1.48% +0.55% Change
More quotes
Financials ( DKK)
Sales 2017 116 165 M
EBIT 2017 49 975 M
Net income 2017 37 856 M
Finance 2017 15 549 M
Yield 2017 2,98%
Sales 2018 121 732 M
EBIT 2018 52 179 M
Net income 2018 41 006 M
Finance 2018 16 166 M
Yield 2018 3,31%
P/E ratio 2017 16,60
P/E ratio 2018 14,91
EV / Sales2017 4,15x
EV / Sales2018 3,96x
Capitalization 497 902 M
More Financials
Company
Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related... 
Sector
Pharmaceuticals
Calendar
05/03Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
04/24 NOVO NORDISK A/S : - Reduction of the share capital
04/24 NOVO NORDISK A/S : - Share repurchase programme
04/22 NOVO NORDISK A/S : Leo Club, Novo Nordisk help intellectually challenged kids
04/21 XOMA CORPORATION (NASDAQ : XOMA) Files An 8-K Termination of a Material Definiti..
04/21 NOVO NORDISK A/S : - Reduction of the share capital
04/20 NOVOZYMES A/S : Researchers Submit Patent Application, "Subtilase Variants", for..
04/20 NOVO NORDISK A/S : Patent Issued for Automatic Injection Device with a Top Relea..
04/20 NOVO NORDISK A/S : Researchers from Novo Nordisk Discuss Findings in Proinsulin ..
04/20 FINDINGS FROM NOVO NORDISK YIELDS NE : Pharmacokinetic and...
04/18 NOVO NORDISK A/S (ADR)(NYSE : NVO) Recognizes The Hemophilia Community
More news
Sector news : Pharmaceuticals - NEC
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
04/25DJNasdaq Composite Tops 6000 for First Time
04/25DJASTRAZENECA : Lung Cancer Treatment Approved in EU
04/25DJELI LILLY AND : Working to Cut Costs
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/25Novo Nordisk A/S upgraded by Zacks Investment Research to hold.  
04/24Novo Nordisk's New Hemophilia-B Drug Will Have A Hard Time Getting Through FD.. 
04/24$XOMA (-4.9% pre) Xoma receieves notice to terminate license agreement from N..
1
04/23Douglas Lane & Associates LLC Sells 28,228 Shares of Novo Nordisk A/S $NV.. 
04/22XOMA -9.6% as Novo Nordisk cancels exclusive deal  
More tweets
Qtime:43
News from SeekingAlpha
04/24 Novo Nordisk's New Hemophilia-B Drug Will Have A Hard Time Getting Through FD..
04/21 XOMA -9.6% as Novo Nordisk cancels exclusive deal
04/19 A REAL DIVIDEND GROWTH MACHINE : Q1 2017 Review
04/17 MAYBE THE WORLD SHOULD SPEND MORE ON : Implications
04/13 Large Cap Biotech Review Pre-Earnings, Part 2
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 270  DKK
Spread / Average Target 6,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-0.39%73 277
JOHNSON & JOHNSON7.13%334 605
ROCHE HOLDING LTD.10.49%223 016
PFIZER INC.3.88%201 045
NOVARTIS AG2.16%199 772
MERCK & CO., INC.5.83%170 797
More Results